Key Highlights

  • This company's shares are trading at $0.38 in Wednesday's session, up 49.40%.
  • The company reported preliminary positive data from the open-label extension portion of its PALISADE-4 Phase 3 study of fasedienol for social anxiety disorder.
  • Fasedienol was well-tolerated with no new drug-related safety findings after as-needed use for up to 12 months, with clinically relevant improvement observed on both clinician-administered and patient-reported scales.
  • The company is preparing to meet with the FDA this quarter to discuss a proposed new registrational Phase 3 trial.

Extension Study Data Drives the Rally

Vistagen (NASDAQ:VTGN) shares are surging after the company reported preliminary positive data from the open-label extension portion of its PALISADE-4 Phase 3 study evaluating fasedienol nasal spray for the acute treatment of social anxiety disorder. In an analysis of 322 subjects who continued into the extension portion, fasedienol was well-tolerated with no new drug-related safety findings after as-needed use for up to 12 months, and improvement was observed over time on both the clinician-administered Liebowitz Social Anxiety Scale and the patient-reported Social Phobia Inventory.

Improvement Built Steadily Over Four Months

At study entry, patients had a mean baseline score indicating very severe social anxiety, and by month four, mean improvement on the Liebowitz scale reached 31.4 points, with 65% of patients achieving at least a 20-point improvement. The company's chief medical officer said the findings reflect the potential impact of repeated, as-needed use of fasedienol in the everyday settings where social anxiety symptoms actually occur, adding to a growing body of evidence supporting the drug's clinical utility.

A Novel Nose-to-Brain Approach Heading Toward the FDA

Vistagen is a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain. The company is preparing to meet with the FDA during the current quarter to discuss a proposed new registrational Phase 3 clinical trial of fasedienol, a step that would follow the drug's earlier randomized PALISADE-4 study, which narrowly missed its primary endpoint in the overall population but showed statistically significant benefit in a subgroup of patients with very severe social anxiety.